Pharmexa extends and updates license agreement with H. Lundbeck A/S
18-Dec-2007 -
Pharmexa and Lundbeck have entered into a new agreement, which is an extension of the original research and license agreement from April 2000, wherein H. Lundbeck received a global and exclusive license to PX106, a vaccine against Alzheimer's disease, developed by Pharmexa.
With the updated ...
Alzheimer's disease
license agreements
Lundbeck
+3